KBC verkoopt belang Movetis aan Shire: http://tiny.cc/3519b
posted 1 day ago
Reports, presentations and many other documents are downloadable and give detailed information about the life sciences sector and FlandersBio. FlandersBio members can contact us for more customised information prepared by our in-house experts.
This life sciences guide lists the many advantages Flanders offers to prospective life sciences investors, gives an overview of existing life sciences activities in Flanders, and describes the facilities available to companies considering relocating to the region.
Here you can download the FlandersBio corporate flyer, with more information about our goals and activities.
Flanders is home to more than 140 life sciences companies with biotech activities. In total, they employ more than 13 000 people. The biotech sector ranks 3rd for R&D investments in Flanders.
Flanders offers many assets to startup your life sciences business. Read more about it in this document.
This brochure gives a clear overview of the financing sources on which companies can rely for the start-up or development of their company. This document is only consultable by FlandersBio member organisations.
Deze brochure geeft een duidelijk overzicht van de financieringsbronnen waarop bedrijven een beroep kunnen doen voor het opstarten of verder uitbouwen van hun onderneming. Dit document is enkel consulteerbaar door medewerkers van FlandersBio-ledenorganisaties.
This brochure, made by Flanders Investment & Trade (FIT) in collaboration with FlandersBio, provides an overview of how Flanders offers life sciences companies a long and successful tradition in discovery and development, and production and logistics.
Cinbios is the Cluster of Industrial Biotech Solutions. More info can be found in this brochure or on www.cinbios.be. This flyer is only available in Dutch.
FlandersBio is one of the partners in the European project Euregional PACT II, the Euregional Platform for Advancing Cancer Treatment. You can find more information in this flyer.
If you use the FlandersBio logo in your PowerPoint presentation or any other document, please let us know (jonas.debacker@flandersbio.be). We can also provide you with a high resolution for print.
In this report, from the Dutch COGEM, you can find a detailed analysis of the fast developments in biotechnology. This report is only available in Dutch.
On 1 December 2009, the new Belgian legislation on the procurement and use of human cells and tissues entered into force. As a consequence, Belgium has satisfied the requirement to transpose into Belgian law Directive 2004/23/EC of the European Parliament and European Council of 31 March 2004.
This will ensure that Belgian legislation takes into better account the recent scientific developments in molecular and cellular biotechnology that permit innovations in treatment such as gene therapy, somatic cell therapy and tissue engineering.
A small and specialised sector of research-intensive SMEs in the biotechnology industry focuses on the discovery and development of innovative biopharmaceutical medicines for human healthcare. Within the last 10-15 years, this biopharmaceutical sector has become one of the most research-intensive sectors with a great potential for delivering innovative human medicines in the future.
This Special Report provides a comprehensive overview of signifcant trends in the life Sciences presented at the congress and offers impressions of the atmosphere in the sessions, in the exhibition and at the official reception.
FlandersBio was one of the partners in making this special about innovation that appeared together with the Belgian quality newspaper De Standaard in October 2009. This special is only available in Dutch.
FlandersBio was one of the partners in making this biotech special that appeared together with the Belgian quality newspaper De Standaard in April 2009. This special is only available in Dutch.
